Three scientists whose work created an entirely new way of studying the brain have been honoured with this year's Nobel Prize in Physiology or Medicine. US psychiatrist and neurologist Karl Deisseroth, together with his German colleagues Peter Hegemann and Georg Nagel, received the award for founding the field of optogenetics, a technique that allows researchers to control specific nerve cells using light.
The announcement, made by the Nobel committee, recognises research that has fundamentally changed how scientists investigate the human brain. According to the committee, the trio's discoveries laid the foundation for a new era in neuroscience. Their work has made it possible to identify the neural circuits responsible for particular memories, feelings and behaviours — circuits that are directly relevant to neurological and psychiatric disorders.
Optogenetics works by making individual nerve cells responsive to light. Researchers introduce light-sensitive proteins into targeted neurons, then use pulses of light to switch those cells on or off with remarkable precision. This gives scientists an unprecedented level of control, allowing them to observe in real time how specific groups of cells contribute to brain activity and behaviour.
Before this technique emerged, studying the brain's circuitry was a far cruder exercise. Scientists could record electrical activity or remove or stimulate broad regions of tissue, but they could not easily isolate individual cell types within the dense, intertwined networks of the nervous system. Optogenetics solved that problem by combining genetics and optics, offering a tool that could activate or silence chosen neurons at the flick of a light switch.
The implications for medicine are significant. Because the method can pinpoint the cells behind particular behaviours and feelings, it offers a way to investigate what goes wrong in conditions such as depression, anxiety, addiction and neurodegenerative disease. By revealing the neural circuits involved in these disorders, the technique gives researchers targets to aim at when developing future treatments.
Beyond understanding disease, optogenetics is already being explored as a therapy in its own right. In clinical medicine, researchers are using the method in attempts to restore sight in people with visual impairment. The approach involves introducing light-sensitive proteins into surviving cells of the retina so that they can respond to light again, potentially bypassing damaged photoreceptors that normally convert light into nerve signals.
The award also highlights the collaborative nature of modern science. Deisseroth, based in the United States, worked alongside Hegemann and Nagel in Germany, and their combined expertise in psychiatry, neuroscience and biophysics proved essential to developing the technology. Their partnership illustrates how breakthroughs often emerge when researchers from different disciplines and countries pool their knowledge.
Karl Deisseroth is a practising psychiatrist as well as a neurologist and researcher, a background that has shaped his interest in the biological roots of mental experience. Peter Hegemann and Georg Nagel brought complementary strengths in the study of light-sensitive proteins, work that provided the molecular tools on which optogenetics depends. Together, their contributions transformed an ambitious idea into a widely used laboratory method.
Since its introduction, optogenetics has spread through neuroscience laboratories around the world. It is now a standard part of the research toolkit, used to probe everything from memory formation and decision-making to the neural underpinnings of fear and reward. The sheer breadth of its applications is one reason the Nobel committee described the work as opening a new era in the field.
The prize also carries symbolic weight for the field of brain research. Mental health conditions and neurological disorders place an enormous burden on individuals and health systems worldwide, yet their biological causes have often remained stubbornly opaque. By providing a way to trace the circuits behind specific feelings and behaviours, optogenetics offers hope that these conditions can eventually be understood — and treated — with far greater precision.
The Nobel Assembly's decision reflects a broader trend in which medicine honours fundamental discoveries that reshape entire disciplines, even if their most visible clinical benefits are still emerging. Optogenetics sits at that intersection: it is firmly established as a research method, while its therapeutic potential, including in vision restoration, continues to be tested.
For patients and families affected by psychiatric and neurological illness, the recognition is a reminder that basic science can chart a path toward better care. Each experiment that uses light to switch a neuron on or off adds another piece to the puzzle of how the brain produces thoughts, emotions and actions — and, ultimately, what happens when those processes go awry.
The three laureates now join the distinguished ranks of Nobel winners in physiology or medicine, a list that includes many of the scientists who shaped modern understanding of the body and brain. Their achievement is a testament to the value of curiosity-driven research, which often delivers its greatest rewards long after the first experiments are conducted.
As researchers continue to refine optogenetics and extend it into new areas of medicine, the award serves as both a celebration of past discovery and a prompt for future work. The ability to control nerve cells with light has given science a powerful lens on the brain, and the questions it allows researchers to ask are only just beginning to be answered.
(0)